{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:37:33Z","timestamp":1791632253394,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jad.2026.121802","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T15:41:56Z","timestamp":1776440516000},"page":"121802","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Depressed mood and suicidal thoughts reporting with GLP-1 receptor agonists in type 2 diabetes: A WHO VigiBase study"],"prefix":"10.1016","volume":"407","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6991-9523","authenticated-orcid":false,"given":"Mohammed","family":"Aboukaoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bosmat","family":"Hoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Weiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Revital","family":"Amiaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jad.2026.121802_bb0005","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1111\/dom.15616","article-title":"Cross-sectional, case-control and longitudinal associations between exposure to glucagon-like peptide-1 receptor agonists and the dispensing of antidepressants","volume":"26","author":"Almeida","year":"2024","journal-title":"Diabetes Obes. Metab."},{"issue":"18","key":"10.1016\/j.jad.2026.121802_bb0010","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.7314\/APJCP.2015.16.18.8567","article-title":"Survival analysis of patients with breast cancer using Weibull parametric model","volume":"16","author":"Baghestani","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.jad.2026.121802_bb0015","doi-asserted-by":"crossref","first-page":"107415","DOI":"10.1016\/j.psyneuen.2025.107415","article-title":"The effect of GLP-1RAs on mental health and psychotropics-induced metabolic disorders: a systematic review","volume":"176","author":"Breit","year":"2025","journal-title":"Psychoneuroendocrinology"},{"issue":"5","key":"10.1016\/j.jad.2026.121802_bb0020","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40264-023-01392-3","article-title":"Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications: a systematic review","volume":"47","author":"Calvarysky","year":"2024","journal-title":"Drug Saf."},{"key":"10.1016\/j.jad.2026.121802_bb0025","article-title":"Glucagon-like peptide-1 receptor agonist semaglutide through the lens of psychiatry: a systematic review of potential benefits and risks","author":"Carminati","year":"2025","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.jad.2026.121802_bb0030","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/dom.70175","article-title":"Risk of depression with GLP-1 receptor agonists use in overweight or obese adults with type 2 diabetes: a new-user, active-comparator cohort study","volume":"28","author":"Chang","year":"2026","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.jad.2026.121802_bb0035","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jagp.2023.08.010","article-title":"The antidepressant effects of GLP-1 receptor agonists: a systematic review and meta-analysis","volume":"32","author":"Chen","year":"2024","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"9","key":"10.1016\/j.jad.2026.121802_bb0040","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Das","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.jad.2026.121802_bb0045","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"issue":"11","key":"10.1016\/j.jad.2026.121802_bb0050","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3390\/jcm7110445","article-title":"Risk of depression and suicidality among diabetic patients: a systematic review and meta-analysis","volume":"7","author":"Elamoshy","year":"2018","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jad.2026.121802_bb0055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev-soc-071913-043455","article-title":"Endogenous selection bias: the problem of conditioning on a collider variable","volume":"40","author":"Elwert","year":"2014","journal-title":"Annu. Rev. Sociol."},{"key":"10.1016\/j.jad.2026.121802_bb0060","author":"European Medicines Agency"},{"issue":"1","key":"10.1016\/j.jad.2026.121802_bb0065","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41398-025-03234-5","article-title":"The interface of depression and diabetes: treatment considerations","volume":"15","author":"Fanelli","year":"2025","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2026.121802_bb0070","author":"FDA"},{"issue":"13","key":"10.1016\/j.jad.2026.121802_bb0075","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.3390\/jcm13133729","article-title":"All GLP-1 agonists should, theoretically, cure Alzheimer\u2019s dementia but dulaglutide might be more effective than the others","volume":"13","author":"Fessel","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jad.2026.121802_bb0080","author":"Food and Drug Administration"},{"issue":"9","key":"10.1016\/j.jad.2026.121802_bb0085","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1161\/CIRCULATIONAHA.105.596130","article-title":"Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks","volume":"114","author":"Gadde","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jad.2026.121802_bb0090","doi-asserted-by":"crossref","first-page":"100127","DOI":"10.1016\/j.obpill.2024.100127","article-title":"Glucagon-like receptor-1 agonists for obesity: weight loss outcomes, tolerability, side effects, and risks","volume":"12","author":"Ghusn","year":"2024","journal-title":"Obes. Pillars"},{"key":"10.1016\/j.jad.2026.121802_bb0095","doi-asserted-by":"crossref","first-page":"118163","DOI":"10.1016\/j.ejmech.2025.118163","article-title":"Unraveling the safety profile of GLP-1 receptor agonists: mechanistic insights with a focus on semaglutide","volume":"300","author":"He","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.jad.2026.121802_bb0100","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2165\/11635890-000000000-00000","article-title":"Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection","volume":"26","author":"H\u00f6lscher","year":"2012","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.jad.2026.121802_bb0105","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/nyas.13217","article-title":"Cortisol dysregulation: the bidirectional link between stress, depression, and type 2 diabetes mellitus","volume":"1391","author":"Joseph","year":"2017","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.jad.2026.121802_bb0110","doi-asserted-by":"crossref","first-page":"24433","DOI":"10.1038\/s41598-024-75965-2","article-title":"The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy","volume":"14","author":"Kornelius","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jad.2026.121802_bb0115","series-title":"Springer Handbook of Engineering Statistics","first-page":"63","article-title":"Weibull distributions and their applications","author":"Lai","year":"2006"},{"issue":"2","key":"10.1016\/j.jad.2026.121802_bb0120","doi-asserted-by":"crossref","first-page":"A4","DOI":"10.1176\/appi.neuropsych.20230226","article-title":"Glucagon-like peptide 1: an introduction and possible implications for neuropsychiatry","volume":"36","author":"L\u00f3pez-Ojeda","year":"2024","journal-title":"J. Neuropsychiatr. Clin. Neurosci."},{"issue":"12","key":"10.1016\/j.jad.2026.121802_bb0125","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1176\/appi.ajp.20241087","article-title":"Glucagon-like peptide-1 receptor agonists and suicidality: association versus causation and the need for ongoing surveillance","volume":"182","author":"McIntyre","year":"2025","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2026.121802_bb0130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/14740338.2023.2295397","article-title":"The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"23","author":"McIntyre","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"issue":"7","key":"10.1016\/j.jad.2026.121802_bb0135","doi-asserted-by":"crossref","first-page":"e70661","DOI":"10.1002\/brb3.70661","article-title":"Efficacy and safety of glucagon-like peptide-1 agonists for psychiatric symptoms: a systematic review","volume":"15","author":"Meshkat","year":"2025","journal-title":"Brain Behav."},{"key":"10.1016\/j.jad.2026.121802_bb0140","doi-asserted-by":"crossref","first-page":"944243","DOI":"10.3389\/fncel.2022.944243","article-title":"Dopamine D2-subtype receptors outside the blood-brain barrier mediate enhancement of mesolimbic dopamine release and conditioned place preference by intravenous dopamine","volume":"16","author":"Obray","year":"2022","journal-title":"Front. Cell. Neurosci."},{"issue":"7","key":"10.1016\/j.jad.2026.121802_bb0145","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamapsychiatry.2025.0679","article-title":"Glucagon-like peptide 1 receptor agonists and mental health: a systematic review and meta-analysis","volume":"82","author":"Pierret","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2026.121802_bb0150","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12991-024-00490-5","article-title":"On mental pain and suicide risk in modern psychiatry","volume":"23","author":"Pompili","year":"2024","journal-title":"Ann. General Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2026.121802_bb0155","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"3","key":"10.1016\/j.jad.2026.121802_bb0160","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1176\/jnp.13.3.318","article-title":"Applying Bradford Hill\u2019s criteria for causation to neuropsychiatry: challenges and opportunities","volume":"13","author":"van Reekum","year":"2001","journal-title":"J. Neuropsychiatr. Clin. Neurosci."},{"issue":"4","key":"10.1016\/j.jad.2026.121802_bb0165","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S2215-0366(26)00014-3","article-title":"Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study","volume":"13","author":"Taipale","year":"2026","journal-title":"Lancet Psychiatry"},{"issue":"11","key":"10.1016\/j.jad.2026.121802_bb0170","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1001\/jamainternmed.2024.4369","article-title":"GLP-1 receptor agonist use and risk of suicide death","volume":"184","author":"Ueda","year":"2024","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.jad.2026.121802_bb0175","author":"Uppsala Monitoring Center"},{"issue":"4","key":"10.1016\/j.jad.2026.121802_bb0180","doi-asserted-by":"crossref","first-page":"R169","DOI":"10.1530\/EJE-16-0952","article-title":"Management of endocrine disease: suicide risk in patients with diabetes: a systematic review and meta-analysis","volume":"177","author":"Wang","year":"2017","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"10.1016\/j.jad.2026.121802_bb0185","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s40120-025-00724-y","article-title":"Are glucagon-like peptide-1 (GLP-1) receptor agonists central nervous system (CNS) penetrant: a narrative review","volume":"14","author":"West","year":"2025","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.jad.2026.121802_bb0190","author":"World Health Organization"},{"key":"10.1016\/j.jad.2026.121802_bb0195","doi-asserted-by":"crossref","first-page":"1613610","DOI":"10.3389\/fphar.2025.1613610","article-title":"Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis","volume":"16","author":"Xie","year":"2025","journal-title":"Front. Pharmacol."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726006531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726006531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T13:46:04Z","timestamp":1777470364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032726006531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":39,"alternative-id":["S0165032726006531"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2026.121802","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Depressed mood and suicidal thoughts reporting with GLP-1 receptor agonists in type 2 diabetes: A WHO VigiBase study","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2026.121802","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"121802"}}